SC 13D/A 1 sc13da209076047_12272021.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 2)¹

Enzo Biochem, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

294100102

(CUSIP Number)

BRADLEY L. RADOFF

2727 Kirby Drive

Unit 29L

Houston, Texas 77098

STEVE WOLOSKY

RYAN NEBEL

OLSHAN FROME WOLOSKY LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

December 3, 2021

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 294100102

NAME OF REPORTING PERSON

The Radoff Family Foundation

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☒

(b) ☐

SEC USE ONLY

SOURCE OF FUNDS

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

☐

CITIZENSHIP OR PLACE OF ORGANIZATION

TEXAS

NUMBER OF

SOLE VOTING POWER

BENEFICIALLY

400,000

OWNED BY

SHARED VOTING POWER

EACH

REPORTING

- 0 -

PERSON WITH

SOLE DISPOSITIVE POWER

400,000

SHARED DISPOSITIVE POWER

- 0 -

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

400,000

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

☐

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

Less than 1%

TYPE OF REPORTING PERSON

CUSIP No. 294100102


	1	NAME OF REPORTING PERSON

			Bradley L. Radoff
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	SOURCE OF FUNDS

			PF, OO
	5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				☐


	6	CITIZENSHIP OR PLACE OF ORGANIZATION

			USA
NUMBER OF			7	SOLE VOTING POWER
SHARES
BENEFICIALLY					4,298,100
OWNED BY			8	SHARED VOTING POWER
EACH
REPORTING					- 0 -
PERSON WITH			9	SOLE DISPOSITIVE POWER

					4,298,100
			10	SHARED DISPOSITIVE POWER

					- 0 -
	11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			4,298,100
	12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES				☐


	13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

			8.9%
	14	TYPE OF REPORTING PERSON

			IN

CUSIP No. 294100102


	1	NAME OF REPORTING PERSON

			Lorrie A. Carr
	2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☒
						(b) ☐

	3	SEC USE ONLY


	4	SOURCE OF FUNDS


	5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				☐


	6	CITIZENSHIP OR PLACE OF ORGANIZATION

			USA
NUMBER OF			7	SOLE VOTING POWER
SHARES
BENEFICIALLY					- 0 -
OWNED BY			8	SHARED VOTING POWER
EACH
REPORTING					- 0 -
PERSON WITH			9	SOLE DISPOSITIVE POWER

					- 0 -
			10	SHARED DISPOSITIVE POWER

					- 0 -
	11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

			- 0 -
	12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES				☐


	13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

			0%
	14	TYPE OF REPORTING PERSON

			IN

CUSIP No. 294100102

The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

Item 3.

Source and Amount of Funds or Other Consideration.

Item 3 is hereby amended and restated in its entirety to read as follows:

The Shares purchased by the Radoff Foundation were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 400,000 Shares directly owned by the Radoff Foundation is approximately $1,340,356, including brokerage commissions.

The Shares directly owned by Mr. Radoff were purchased with personal funds (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 3,898,100 Shares directly owned by Mr. Radoff is approximately $12,452,239, including brokerage commissions.

Item 5.

Interest in Securities of the Issuer.

Items 5(a) – (c) are hereby amended and restated in their entirety to read as follows:

The aggregate percentage of Shares reported owned by each person named herein is based upon 48,471,771 Shares outstanding as of December 1, 2021, which is the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on December 15, 2021.

Radoff Foundation

(a)

As of the date hereof, the Radoff Foundation directly beneficially owns 400,000 Shares.

Percentage: Less than 1%

(b)

1. Sole power to vote or direct vote: 400,000
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 400,000
4. Shared power to dispose or direct the disposition: 0

Mr. Radoff

(a)

As of the date hereof, Mr. Radoff directly beneficially owns 3,898,100 Shares. As a director of the Radoff Foundation, Mr. Radoff may be deemed to beneficially own the 400,000 Shares owned by the Radoff Foundation.

Percentage: Approximately 8.9%

(b)

1. Sole power to vote or direct vote: 4,298,100
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 4,298,100
4. Shared power to dispose or direct the disposition: 0

CUSIP No. 294100102

Ms. Carr

(a)

As of the date hereof, Ms. Carr does not beneficially own any Shares.

Percentage: 0%

(b)

1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 0

Each Reporting Person may be deemed to be a member of a “group” with the other Reporting Persons for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, and such group may be deemed to beneficially own the 4,298,100 Shares owned in the aggregate by all of the Reporting Persons. Each Reporting Person disclaims beneficial ownership of the Shares that he, she or it does not directly own.

(c)

The transactions in the securities of the Issuer by the Reporting Persons since the filing of the Amendment No. 1 to the Schedule 13D are set forth in Schedule B and are incorporated herein by reference. All such transactions were effected in the open market unless otherwise noted therein.

CUSIP No. 294100102

SIGNATURES

After reasonable inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: December 27, 2021

The Radoff Family Foundation

By:	/s/ Bradley L. Radoff
	Name:	Bradley L. Radoff
	Title:	Director

/s/ Bradley L. Radoff

Bradley L. Radoff

Individually and as attorney-in-fact for Lorrie A. Carr

CUSIP No. 294100102

SCHEDULE B

Transactions in the Securities of the Issuer Since the Filing of the Amendment No. 1 to the Schedule 13D

Nature of the Transaction

Amount of Securities

Purchased/(Sold)

Price ($)

Date of

Purchase/Sale

BRADLEY L. RADOFF

Purchase of Common Stock	36,856	3.2784	10/22/2021
Purchase of Common Stock	10,000	3.3503	10/25/2021
Purchase of Common Stock	18,144	3.3068	10/26/2021
Purchase of Common Stock	15,000	3.3039	10/27/2021
Purchase of Common Stock	15,000	3.3501	11/02/2021
Purchase of Common Stock	1,000	3.4200	11/03/2021
Purchase of Common Stock	9,000	3.3359	11/05/2021
Purchase of Common Stock	15,000	3.3700	11/09/2021
Purchase of Common Stock	15,000	3.3910	11/10/2021
Purchase of Common Stock	139,774	3.3700	11/17/2021
Purchase of Common Stock	10,226	3.3975	11/17/2021
Purchase of Common Stock	5,000	3.4047	11/18/2021
Purchase of Common Stock	15,000	3.3937	11/19/2021
Purchase of Common Stock	20,000	3.2332	11/23/2021
Purchase of Common Stock	20,000	3.2344	11/24/2021
Purchase of Common Stock	25,000	3.4175	11/26/2021
Purchase of Common Stock	30,000	3.3395	11/29/2021
Purchase of Common Stock	25,000	3.4362	11/30/2021
Purchase of Common Stock	26,000	3.4404	12/01/2021
Purchase of Common Stock	27,000	3.3652	12/02/2021
Purchase of Common Stock	25,000	3.3077	12/03/2021
Purchase of Common Stock	32,000	3.3077	12/06/2021
Purchase of Common Stock	17,000	3.4105	12/07/2021
Purchase of Common Stock	5,000	3.5717	12/08/2021
Purchase of Common Stock	8,000	3.6382	12/09/2021
Purchase of Common Stock	11,000	3.5513	12/10/2021
Purchase of Common Stock	5,000	3.6211	12/13/2021
Purchase of Common Stock	14,100	3.4515	12/14/2021
Purchase of Common Stock	13,000	3.4302	12/15/2021
Purchase of Common Stock	31,500	3.2659	12/16/2021
Purchase of Common Stock	12,900	3.2371	12/17/2021
Purchase of Common Stock	12,500	3.2127	12/20/2021
Purchase of Common Stock	18,000	3.2498	12/21/2021

SEC Form SC 13D/A filed by Enzo Biochem, Inc. (Amendment)